Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
about
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@ast
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@en
type
label
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@ast
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@en
prefLabel
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@ast
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@en
P2093
P2860
P50
P1433
P1476
Addition of boceprevir to PEG- ...... data from the ANRS HC27 study.
@en
P2093
ANRS HC27 BOCEPREVIH Study Group
Alain Renault
Alissa Naqvi
Caroline Solas
Eric Bellissant
Jade Ghosn
Jean-Michel Molina
Laurent Alric
Lionel Piroth
Marc Bourlière
P2860
P356
10.1080/15284336.2015.1135553
P577
2016-02-11T00:00:00Z